Pfizer taps CytoReason’s machine learning platform for drug discovery

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Dr_Microbe)
(Image: Getty/Dr_Microbe)

Related tags CytoReason machine learning

CytoReason today announced a collaboration with Pfizer – as the machine learning company eyes future partnerships with industry leaders to up the accuracy of its models and affect decision-making throughout the drug development pipeline, says CEO.

CytoReason’s machine learning platform is based on its “cell-centered models” of cellular activity per disease and tissue, and uses both proprietary and public data.

“This collaboration allows us to demonstrate … how we’re affecting decision-making throughout the pipeline, from discovery through validation of targets, through POC [proof of concept] phases and later clinical stages,” ​CytoReason CEO David Harel told us.

Prior to today’s announcement, the company had been working with Pfizer for some time, and the past several months provided the pharma giant the opportunity “to see the quality and strength of our models,”​ Harel said.

Read: From mouse to man: New machine-learning model reduces number of ‘wasted experiments’

Under the agreement, CytoReason will receive payments potentially equaling up to low double-digit millions (in US dollars) for technology access fees, research support, and certain success-based payments.

The collaboration will focus on immunology, immune-oncology, inflammation, as well as certain dermatology indications, and will enable CytoReason to improve its models across these areas.

“Every new data set, every new trial, every new collaboration we have is improving the accuracy of the model,”​ Harel said.

Moving forward, the company is looking to continue and collaborations with leaders in the industry.

Harel explained, “Part of our compensation for the work and the models and the IP is subject to the success of the programs that we are involved in, so for us, it is important to focus on companies that we know have the track record and expertise to deliver drugs to the market.”

CytoReason is currently working with four of the top ten large pharma companies – and will continue to expand these collaborations, which enable it to improve its models, Harel added. 

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more